WFH 2018 World Congress
| Agenda | |
|---|---|
| Welcome | Karl Mahler, Head of Investor Relations |
| Hemophilia A without inhibitors remains an unmet medical need | Cristin Hubbard, Lifecycle Leader Hemlibra (emicizumab) |
| HAVEN 3: Phase 3 study of emicizumab prophylaxis in persons with hemophilia A without inhibitors | Johnny Mahlangu, MBBCh, MMed, Haemophilia Comprehensive Care Centre, Faculty of Health Sciences, University of the Witwatersrand and NHLS, Johannesburg, South Africa |
| HAVEN 4: Phase 3 study of emicizumab prophylaxis given every 4 weeks in persons with hemophilia A with and without inhibitors; additional comments | Gallia Levy, MD, Associate Group Medical Director Hematology |
| Q&A |
Please register to access the replay* *Privacy notice